ArticleInternational journal of health policy and management2022
Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook".
Article in International journal of health policy and management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Competencies for health technology assessment professionals: a scoping review and content analysis.International journal of technology assessment in health care · 2026Article
- Health technology reassessment and disinvestment instruments: a scoping review.Health research policy and systems · 2026Review
- Insights and implications: an analysis of the studies undertaken by Health Technology Assessment in India (HTAIn).Health research policy and systems · 2025Article
- Delivering a national de-adoption programme: a documentary analysis of local commissioning policy compliance with England's Evidence-based Interventions programme (EBI).BMC health services research · 2025Article
- Deliberative process of health technology reassessment by health technology assessment agency in Korea.International journal of technology assessment in health care · 2024Article
- Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries.Future oncology (London, England) · 2024Article
- History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo develop a knowledge translation (KT) tool that will provide guidance to stakeholders actively planning or considering implementation of a health technology reassessment (HTR) initiative.
methodsThe KT tool is an international and collaborative endeavour between HTR researchers in Canada, Australia, and the United Kingdom. Evidence from a meta-review of documented international HTR experiences and approaches provided the conceptual framing for the KT tool. The purpose, audience, format, and overall scope and content of the tool were established through iterative discussions and consensus. An initial version of the KT tool was beta-tested with an international community of relevant stakeholders (i.e., potential users) at the Health Technology Assessment International 2018 annual meeting.
resultsAn open access workbook, referred to as the HTR playbook, was developed. As a KT tool, the HTR playbook is intended to simplify the complex HTR planning process by navigating users step-by-step through 6 strategic domains: characteristics of the candidate health technology (
conclusionThe HTR playbook is intended to enhance a user's ability to successfully complete a HTR by helping them systematically consider the different elements and approaches to achieve the right care for the patient population in question.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.